8.35
-0.06 (-0.71%)
| Penutupan Terdahulu | 8.41 |
| Buka | 8.37 |
| Jumlah Dagangan | 1,022,053 |
| Purata Dagangan (3B) | 2,147,479 |
| Modal Pasaran | 1,447,241,984 |
| Harga / Jualan (P/S) | 151.28 |
| Harga / Buku (P/B) | 2.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | -1,105.21% |
| EPS Cair (TTM) | -2.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -23.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.54% |
| Nisbah Semasa (MRQ) | 19.96 |
| Aliran Tunai Operasi (OCF TTM) | -271.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -155.22 M |
| Pulangan Atas Aset (ROA TTM) | -28.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Relay Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.88 |
|
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.48% |
| % Dimiliki oleh Institusi | 105.68% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nextech Invest Ltd. | 31 Dec 2024 | 3,846,409 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (Oppenheimer, 67.67%) | Beli |
| Median | 13.50 (61.68%) | |
| Rendah | 13.00 (Wells Fargo, 55.69%) | Beli |
| Purata | 13.50 (61.68%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 7.73 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Oppenheimer | 26 Jan 2026 | 14.00 (67.66%) | Beli | 7.43 |
| Wells Fargo | 12 Dec 2025 | 13.00 (55.69%) | Beli | 8.03 |
| 07 Nov 2025 | 6.00 (-28.14%) | Pegang | 6.05 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Dec 2025 | Pengumuman | Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 |
| 06 Nov 2025 | Pengumuman | Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates |
| 03 Nov 2025 | Pengumuman | Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November |
| 30 Oct 2025 | Pengumuman | Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |